Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Halozyme Therapeutics Inc

HALO ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Large Cap Analyst: BUY

Last Close

$110.19

▼ -0.51%

Market Cap $12.51B · Vol 374.89K

Key Metrics

P/E Ratio

32.92

FWD: 10.96

Market Cap

$12.51B

Large Cap

Div Yield

N/A

EPS Growth

+113.37%

YoY

RSI (14)

68.66

Momentum

Beta

0.88

vs Market

52W High

$111.02

0.74% below

52W Low

$61.23

79.96% above

Volume

374.89K

Avg 632.87K

P/B

162.39

Price-to-book

ROE

246.97%

Return on equity

Free Float

98.55%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Halozyme Therapeutics Inc (HALO) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HALO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.59%

+32.39%

+53.90%

+57.37%

YTD

+63.73%

+50.12%

+169.41%

+160.99%

Financials & Valuation

TTM · Annual

Total Revenue	$1.40B
Net Income	$316.89M
Revenue Growth (YoY)	+47.67%
Gross Margin	78.13%
Operating Margin	58.45%
Net Profit Margin	22.69%
ROE	246.97%
ROA · ROIC	20.35% · 16.21%

P/E Ratio	32.92
Forward P/E (FY1)	10.96
PEG Ratio	-1.03
P/S	5.97
P/B	162.39
P/FCF	23.37
EPS Growth	+113.37%
Outstanding Shares	113.50M

Technical Indicators

50-Day SMA	$90.67
200-Day SMA	$74.21
RSI (14)	68.66
Beta	0.88
52-Week High	$111.02
52-Week Low	$61.23

Volume Today	374.89K
Avg Daily Volume (30D)	632.87K
Relative Volume	0.59x
Volatility (10D)	18.53
Volatility (30D)	56.27
Free Float	98.55%

Analyst Consensus

BUY

Current Price $110.19

Mean Target $101.91

52W Low$61.23 52W High$111.02

Current

Target

$61.23 $111.02

Current Analyst target

-7.51% downside risk · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SGX585

ISINUS40637H1095

CountryUnited States of America

Sub-IndustryProprietary & Advanced Pharmaceuticals

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

MRK Merck & Co Inc -1.32% MRK.DE Merck KGaA -1.45% 4151.T Kyowa Kirin Co Ltd -1.09% 326030.KS SK Biopharmaceuticals Co Ltd +0.23% 000100.KS Yuhan Corp +0.00%

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.